Table 2. Trends in usage in SLNM in endometrial cancer.
| Variable | No. (%) | |
|---|---|---|
| Reported usage of SLNM | ||
| Endometrial CA | 46 (23.2) | |
| Cervical CA | 4 (2.0) | |
| Endometrial and cervical CA | 89 (44.9) | |
| No | 59 (29.8) | |
| Percentage of surgeon time using SLNM in endometrial CA (n=133) | ||
| 1%–25% | 9 (6.8) | |
| 26%–50% | 7 (5.3) | |
| 51%–75% | 23 (17.3) | |
| 76%–99% | 61 (45.9) | |
| 100% | 33 (24.8) | |
| Career total of number of SLNM cases for endometrial CA performed | ||
| Less than 10 | 13 (1.0) | |
| 10–50 | 41 (30.4) | |
| 51–100 | 32 (23.7) | |
| 101–200 | 27 (20.0) | |
| 201–500 | 15 (11.1) | |
| Greater than 500 | 4 (3.0) | |
| Surgical platform using SLNM in endometrial CA | ||
| Robotic assisted laparoscopy | 109 (80.7) | |
| Multi-port laparoscopy | 39 (28.9) | |
| Single-site laparoscopy | 3 (2.2) | |
| Laparotomy | 7 (5.2) | |
| Mapping medium used for SLNM in endometrial CA | ||
| Isosulfan blue | 17 (12.6) | |
| Indocyanine Green | 131 (97.0) | |
| Technectium-99 | 4 (3.0) | |
| Other | 1 (0.7) | |
| Proportion of usage of SLNM in endometrial CA histologies | ||
| All histologies without extra-uterine disease | 76 (56.3) | |
| CAH | 26 (19.3) | |
| FIGO1 | 58 (43.0) | |
| FIGO2 | 57 (42.2) | |
| FIGO3 | 30 (22.2) | |
| High-risk histologies (USC, UCC, CS) | 24 (17.8) | |
| Surgeon performing concurrent SLNM with full LND for endometrial CA | ||
| Yes | 85 (63.0) | |
| No | 47 (34.8) | |
| Number of concurrent SLNM cases with full LND for endometrial CA | 25 (2–250) | |
| Surgeon awareness of SLNM rate for endometrial CA | ||
| Yes | 59 (43.7) | |
| No | 73 (54.1) | |
| Unilateral SLNM rate for endometrial CA | 90 (0–100) | |
| Bilateral SLNM rate for endometrial CA | 85 (50–100) | |
| Perceived benefits of SLNM for endometrial CA | ||
| Reduced surgical morbidity | 121 (89.6) | |
| Faster than full lymphadectomy | 86 (63.7) | |
| Reduced lymphedema | 115 (85.2) | |
| Faster recovery time | 28 (20.7) | |
| Reduced blood loss | 55 (40.7) | |
| Detection of small volume disease | 8 (5.9) | |
| Reduced lymphocele/lymphocyst | 3 (2.2) | |
| Other | 5 (3.7) | |
The SLNM mapping rates and number of concurrent SLNM cases are reported as median +/− reported range.
CA, cancer; CAH, complex atypical hyperplasia; CS, carcinosarcoma; FIGO, International Federation of Gynecology and Obstetrics; LND, lymphadenectomy; SLNM, sentinel lymph node mapping; UCC, clear cell carcinoma; USC, uterine serous carcinoma.